Nasdaq · CIK 0001439222
AGIO AGIOS PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing Mar 7, 2025. Close $31.81 on Oct 9, 2026, +42% from the 52-week low and -30% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
AGIOOct 9, 2026 · close 31.81
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AGIOS PHARMACEUTICALS, INC., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 12Weak | sell 610b5-1 | Theodore James Washburn Jr. Principal Accounting Officer | $59k | 1,655 | -26% | +4% from low · -46% from high | |
| 6Weak | sell 610b5-1 | Sarah Gheuens Chief Medical Officer | $142k | 4,005 | -8% | +4% from low · -46% from high | |
| 27Weak | sell 610b5-1 | Brian Goff Chief Executive Officer | $460k | 12,947 | -15% | +4% from low · -46% from high | |
| 2Weak | sell 610b5-1 | Tsveta Milanova Chief Commercial Officer | $60k | 1,681 | -7% | +4% from low · -46% from high | |
| 16Weak | sell 610b5-1 | Cecilia Jones Chief Financial Officer | $81k | 2,275 | -10% | +4% from low · -46% from high | |
| 11Weak | sell 610b5-1 | James William Burns Chief Legal Officer | $142k | 4,005 | -20% | +4% from low · -46% from high | |
| 0Weak | sell10b5-1 | Theodore James Washburn Jr. Principal Accounting Officer | $78k | 2,272 | -29% | +8% from low · -44% from high | |
| 0Weak | sell10b5-1 | Tsveta Milanova Chief Commercial Officer | $90k | 2,804 | -13% | +5% from low · -46% from high | |
| 0Weak | sell10b5-1 | David Scadden director | $9,256 | 200 | -1% | - | |
| 46Moderate | sell 3 | Theodore James Washburn Jr. Principal Accounting Officer | $43k | 772 | -49% | - | |
| 55Moderate | sell 310b5-1 | James William Burns Chief Legal Officer | $1.1M | 21,752 | -58% | - | |
| 40Moderate | sell 310b5-1 | Rahul D. Ballal director | $1.1M | 20,000 | -111% | - |
Congressional trades
5 trades in AGIO disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AGIO Agios Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Aug 20, 2026 | 21 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AGIO Agios Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Mar 3, 2026 | 35 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AGIO Agios Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Dec 11, 2025 | 32 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AGIO Agios Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Apr 17, 2025 | 19 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | AGIO Agios Pharmaceuticals, Inc. - Common Stock | $1,001 to $15k | Jan 29, 2025 | 13 days after the trade |
Transactions
The last 79 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2025 | Krishnan Viswanadhan Chief Corp Dev & Strategy | AGrant or award Restricted stock unitsderivative | +24,300 | $0.00 | $0 | 24,300 | Mar 7, 2025 |
| Mar 5, 2025 | Krishnan Viswanadhan Chief Corp Dev & Strategy | AGrant or award Stock options (right to buy)derivative | +55,374 | $0.00 | $0 | 55,374 | Mar 7, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | MOption exercise Common stock10b5-1 | +3,833 | $0.00 | $0 | 48,235 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Common stock10b5-1 | +777 | $0.00 | $0 | 6,269 | Mar 4, 2025 |
| Mar 1, 2025 | Brian Goff Chief Executive Officer | MOption exercise Common stock10b5-1 | +8,500 | $0.00 | $0 | 87,292 | Mar 4, 2025 |
| Mar 1, 2025 | Tsveta Milanova Chief Commercial Officer | MOption exercise Common stock10b5-1 | +5,667 | $0.00 | $0 | 24,573 | Mar 4, 2025 |
| Mar 1, 2025 | Cecilia Jones Chief Financial Officer | MOption exercise Common stock10b5-1 | +2,000 | $0.00 | $0 | 22,437 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | MOption exercise Common stock10b5-1 | +3,833 | $0.00 | $0 | 19,787 | Mar 4, 2025 |
| Mar 3, 2025 | Sarah Gheuens Chief Medical Officer | SOpen-market sale Common stock10b5-1 | -1,137 | $35.54 | $40k | 47,098 | Mar 4, 2025 |
| Mar 3, 2025 | Brian Goff Chief Executive Officer | SOpen-market sale Common stock10b5-1 | -4,153 | $35.54 | $148k | 83,139 | Mar 4, 2025 |
| Mar 3, 2025 | Tsveta Milanova Chief Commercial Officer | SOpen-market sale Common stock10b5-1 | -1,681 | $35.54 | $60k | 22,892 | Mar 4, 2025 |
| Mar 3, 2025 | Cecilia Jones Chief Financial Officer | SOpen-market sale Common stock10b5-1 | -594 | $35.54 | $21k | 21,843 | Mar 4, 2025 |
| Mar 3, 2025 | James William Burns Chief Legal Officer | SOpen-market sale Common stock10b5-1 | -1,137 | $35.54 | $40k | 18,650 | Mar 4, 2025 |
| Mar 3, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | SOpen-market sale Common stock10b5-1 | -231 | $35.54 | $8,210 | 6,038 | Mar 4, 2025 |
| Mar 1, 2025 | Cecilia Jones Chief Financial Officer | MOption exercise Common stock10b5-1 | +5,667 | $0.00 | $0 | 27,510 | Mar 4, 2025 |
| Mar 1, 2025 | Brian Goff Chief Executive Officer | MOption exercise Common stock10b5-1 | +18,000 | $0.00 | $0 | 101,139 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | MOption exercise Common stock10b5-1 | +4,000 | $0.00 | $0 | 22,650 | Mar 4, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | MOption exercise Common stock10b5-1 | +4,000 | $0.00 | $0 | 51,098 | Mar 4, 2025 |
| Mar 1, 2025 | Tsveta Milanova Chief Commercial Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +12,000 | $0.00 | $0 | 12,000 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Common stock10b5-1 | +2,350 | $0.00 | $0 | 8,388 | Mar 4, 2025 |
| Mar 3, 2025 | Brian Goff Chief Executive Officer | SOpen-market sale Common stock10b5-1 | -8,794 | $35.54 | $313k | 92,345 | Mar 4, 2025 |
| Mar 3, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | SOpen-market sale Common stock10b5-1 | -697 | $35.54 | $25k | 7,691 | Mar 4, 2025 |
| Mar 1, 2025 | Tsveta Milanova Chief Commercial Officer | AGrant or award Stock options (right to buy)derivative10b5-1 | +43,500 | $0.00 | $0 | 43,500 | Mar 4, 2025 |
| Mar 3, 2025 | Sarah Gheuens Chief Medical Officer | SOpen-market sale Common stock10b5-1 | -1,187 | $35.54 | $42k | 49,911 | Mar 4, 2025 |
| Mar 3, 2025 | James William Burns Chief Legal Officer | SOpen-market sale Common stock10b5-1 | -1,187 | $35.54 | $42k | 21,463 | Mar 4, 2025 |
| Mar 3, 2025 | Cecilia Jones Chief Financial Officer | SOpen-market sale Common stock10b5-1 | -1,681 | $35.54 | $60k | 25,829 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Common stock10b5-1 | +2,450 | $0.00 | $0 | 10,141 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | MOption exercise Common stock10b5-1 | +5,667 | $0.00 | $0 | 27,130 | Mar 4, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | MOption exercise Common stock10b5-1 | +5,667 | $0.00 | $0 | 55,578 | Mar 4, 2025 |
| Mar 1, 2025 | Tsveta Milanova Chief Commercial Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -5,667 | $0.00 | $0 | 11,333 | Mar 4, 2025 |
| Mar 1, 2025 | Brian Goff Chief Executive Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +39,000 | $0.00 | $0 | 39,000 | Mar 4, 2025 |
| Mar 1, 2025 | Cecilia Jones Chief Financial Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +12,000 | $0.00 | $0 | 12,000 | Mar 4, 2025 |
| Mar 3, 2025 | Sarah Gheuens Chief Medical Officer | SOpen-market sale Common stock10b5-1 | -1,681 | $35.54 | $60k | 53,897 | Mar 4, 2025 |
| Mar 1, 2025 | Brian Goff Chief Executive Officer | AGrant or award Stock options (right to buy)derivative10b5-1 | +142,500 | $0.00 | $0 | 142,500 | Mar 4, 2025 |
| Mar 1, 2025 | Cecilia Jones Chief Financial Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +15,910 | $0.00 | $0 | 15,910 | Mar 4, 2025 |
| Mar 3, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | SOpen-market sale Common stock10b5-1 | -727 | $35.54 | $26k | 9,414 | Mar 4, 2025 |
| Mar 3, 2025 | James William Burns Chief Legal Officer | SOpen-market sale Common stock10b5-1 | -1,681 | $35.54 | $60k | 25,449 | Mar 4, 2025 |
| Mar 1, 2025 | Cecilia Jones Chief Financial Officer | AGrant or award Stock options (right to buy)derivative10b5-1 | +43,500 | $0.00 | $0 | 43,500 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +12,000 | $0.00 | $0 | 12,000 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +8,085 | $0.00 | $0 | 8,085 | Mar 4, 2025 |
| Mar 1, 2025 | Brian Goff Chief Executive Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -8,500 | $0.00 | $0 | 8,500 | Mar 4, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +12,000 | $0.00 | $0 | 12,000 | Mar 4, 2025 |
| Mar 1, 2025 | Brian Goff Chief Executive Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -18,000 | $0.00 | $0 | 36,000 | Mar 4, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | AGrant or award Stock options (right to buy)derivative10b5-1 | +43,500 | $0.00 | $0 | 43,500 | Mar 4, 2025 |
| Mar 1, 2025 | Cecilia Jones Chief Financial Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -2,000 | $0.00 | $0 | 2,000 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +11,759 | $0.00 | $0 | 11,759 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | AGrant or award Restricted stock unitsderivative10b5-1 | +6,142 | $0.00 | $0 | 6,142 | Mar 4, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -3,833 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 1, 2025 | Cecilia Jones Chief Financial Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -5,667 | $0.00 | $0 | 11,333 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | AGrant or award Stock options (right to buy)derivative10b5-1 | +43,500 | $0.00 | $0 | 43,500 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -777 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -2,350 | $0.00 | $0 | 2,350 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -3,833 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -4,000 | $0.00 | $0 | 4,000 | Mar 4, 2025 |
| Mar 1, 2025 | Sarah Gheuens Chief Medical Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -5,667 | $0.00 | $0 | 11,333 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -4,000 | $0.00 | $0 | 4,000 | Mar 4, 2025 |
| Mar 3, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -2,450 | $0.00 | $0 | 4,900 | Mar 4, 2025 |
| Mar 1, 2025 | James William Burns Chief Legal Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -5,667 | $0.00 | $0 | 11,333 | Mar 4, 2025 |
| Feb 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Common stock10b5-1 | +6,896 | $0.00 | $0 | 7,709 | Feb 5, 2025 |
| Feb 5, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | SOpen-market sale Common stock10b5-1 | -2,272 | $34.39 | $78k | 5,437 | Feb 5, 2025 |
| Feb 1, 2025 | Theodore James Washburn Jr. Principal Accounting Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -6,896 | $0.00 | $0 | 0 | Feb 5, 2025 |
| Jan 3, 2025 | Tsveta Milanova Chief Commercial Officer | MOption exercise Common stock10b5-1 | +8,476 | $0.00 | $0 | 21,710 | Jan 7, 2025 |
| Jan 6, 2025 | Tsveta Milanova Chief Commercial Officer | SOpen-market sale Common stock10b5-1 | -2,804 | $32.18 | $90k | 18,906 | Jan 7, 2025 |
| Jan 3, 2025 | Tsveta Milanova Chief Commercial Officer | MOption exercise Restricted stock unitsderivative10b5-1 | -8,476 | $0.00 | $0 | 8,475 | Jan 7, 2025 |
| Dec 11, 2024 | David Scadden director | MOption exercise Common stock10b5-1 | +200 | $18.09 | $3,618 | 15,683 | Dec 13, 2024 |
| Dec 11, 2024 | David Scadden director | SOpen-market sale Common stock10b5-1 | -200 | $46.28 | $9,256 | 15,483 | Dec 13, 2024 |
| Dec 11, 2024 | David Scadden director | MOption exercise Stock options (right to buy)derivative10b5-1 | -200 | $0.00 | $0 | 29,107 | Dec 13, 2024 |
| Nov 8, 2024 | Theodore James Washburn Jr. Principal Accounting Officer | SOpen-market sale Common stock | -772 | $56.09 | $43k | 813 | Nov 13, 2024 |
| Nov 7, 2024 | Rahul D. Ballal director | MOption exercise Common stock10b5-1 | +10,000 | $25.99 | $260k | 17,992 | Nov 12, 2024 |
| Nov 7, 2024 | James William Burns Chief Legal Officer | SOpen-market sale Common stock10b5-1 | -13,411 | $52.00 | $697k | 24,041 | Nov 12, 2024 |
| Nov 7, 2024 | Rahul D. Ballal director | SOpen-market sale Common stock10b5-1 | -8,132 | $53.32 | $434k | 9,860 | Nov 12, 2024 |
| Nov 7, 2024 | James William Burns Chief Legal Officer | SOpen-market sale Common stock10b5-1 | -8,341 | $52.56 | $438k | 15,700 | Nov 12, 2024 |
| Nov 7, 2024 | Rahul D. Ballal director | SOpen-market sale Common stock10b5-1 | -1,868 | $54.41 | $102k | 7,992 | Nov 12, 2024 |
| Nov 8, 2024 | Rahul D. Ballal director | MOption exercise Common stock10b5-1 | +10,000 | $25.99 | $260k | 17,992 | Nov 12, 2024 |
| Nov 8, 2024 | Rahul D. Ballal director | SOpen-market sale Common stock10b5-1 | -3,571 | $57.24 | $204k | 14,421 | Nov 12, 2024 |
| Nov 8, 2024 | Rahul D. Ballal director | SOpen-market sale Common stock10b5-1 | -4,929 | $58.57 | $289k | 9,492 | Nov 12, 2024 |
| Nov 8, 2024 | Rahul D. Ballal director | SOpen-market sale Common stock10b5-1 | -1,500 | $59.21 | $89k | 7,992 | Nov 12, 2024 |
| Nov 7, 2024 | Rahul D. Ballal director | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 27,947 | Nov 12, 2024 |
| Nov 8, 2024 | Rahul D. Ballal director | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 17,947 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Rahul D. Ballaldirector
- James William BurnsChief Legal Officer
- Sarah GheuensChief Medical Officer
- Brian GoffChief Executive Officer
- Cecilia JonesChief Financial Officer
- Tsveta MilanovaChief Commercial Officer
- David Scaddendirector
- Krishnan ViswanadhanChief Corp Dev & Strategy
- Theodore James Washburn Jr.Principal Accounting Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.